Connect with us

Technology

3D Printing Medical Devices Market size is set to grow by USD 7.07 billion from 2024-2028, Increased demand for personalized or customized medical devices boost the market, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global 3D printing medical devices market size is estimated to grow by USD 7.07 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 25.2%  during the forecast period. Increased demand for personalized or customized medical devices is driving market growth, with a trend towards rising focus on the research for the use of 3D printing process to manufacture living organs and cell structures. However, high initial setup cost of 3d printing facility  poses a challenge. Key market players include 3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

3D Printing Medical Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 25.2%

Market growth 2024-2028

USD 7079.6 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

19.78

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Germany, UK, Japan, and China

Key companies profiled

3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd.

Market Driver

The 3D printing of medical devices, specifically in the field of bioprinting, represents a significant advancement in healthcare technology. This process involves the precise layering of cells, biologic scaffolds, and growth factors to create bioidentical tissue, such as stem cells, skin grafts, and bone and cartilage. Unlike traditional 3D printers that use plastic or metals as raw materials, 3D bioprinters utilize a computer-guided pipette to layer living cells, referred to as bioink, to create artificial living tissues. One of the most promising applications of 3D bioprinting is in organ replacement. This technology holds the potential to address the organ donor shortage and reduce rejections by creating organs that better meet the requirements of the body. For instance, 3D printed bone features a micropore surface that allows osteocytes to adhere, join, and heal better than traditional metal implants. ORGANOVO, a biotechnology company, is pioneering the use of 3D bioprinting to develop in vivo liver tissues for treating rare, life-threatening diseases. Their product, the ExVive 3D Bioprinted Human Liver Tissues, can be used for drug exposure and metabolism studies, offering a valuable alternative to organ transplantation. Allevi and SHIBUYA are among the companies leading the way in 3D bioprinting technology. Allevi introduced the first desktop 3D bioprinter capable of printing living tissues using human cells, while SHIBUYA’s 3D bioprinter is the first cell culture system for building complex cell-based structures. The potential of 3D bioprinting is driving increased R&D efforts in developing devices for this technology. As technological advances continue, 3D printing medical devices are expected to see widespread adoption, fueling the growth of the global 3D printing medical devices market. 

The 3D Printing Medical Devices market is experiencing significant growth due to its ability to produce customized, patient-specific solutions for various medical applications. Stereolithography (SLA) and digital light processing are popular 3D printing technologies used in creating prosthetics implants, orthopedic implants, and wearable medical devices. Dentistry and orthodontics also benefit from 3D printing, with applications including dentures, bone scaffolds, and hearing aids. Tissue-engineered products, remote patient monitoring, telemedicine, and vital signs monitoring are other areas where 3D printing is making an impact. Complex medical procedures, such as implantable and non-implantable medical devices, drug testing, and organ and tissue production, are also being revolutionized by this technology. Computer-aided manufacturing and design, diagnostic centers, medical institutions, and 3D printing laboratories are embracing 3D printing to provide personalized solutions. Laser beam technology, minimally invasive surgery, and surgical equipment are other areas where 3D printing is making a difference. Patient CAD images are used to create patient-specific models and customized implants, including cranial implants for neurosurgery and human skull repairs. Overall, 3D printing is transforming the medical industry by enabling the production of customized, high-quality medical devices in a layer-wise manner. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

The 3D printing medical devices market faces significant challenges due to high capital costs. Equipment for 3D printing or outsourced print service contracts, advanced software for post-processing, and proprietary raw materials contribute to these costs. Desktop FDM or SLA machines cost less than USD5,000, but high-end additive manufacturing printers range from USD200,000 to USD850,000 or even millions. Skilled personnel and training are also necessary, adding to the expenses. A clinical 3D printing lab requires ancillary staff for printing. Production time, ranging from hours to days, limits its use in mass manufacturing. These factors hinder the widespread adoption of 3D printers, potentially impacting the growth of the market negatively.The 3D printing medical devices market is experiencing significant growth due to the advantages it offers in creating customized solutions for various medical needs. However, there are challenges that need to be addressed. For physicians, the use of 3D-printed medical devices in elective surgical procedures requires careful consideration for complex prosthetic limbs and brain designs. Surgeons prefer titanium alloys for surgical tools, but cancer patients benefit from biocompatible materials as drug contact materials. Hearing aid manufacturers are exploring 3D-printed hearing aid devices using biocompatible materials for personalized solutions. CAD/CAM technology and desktop printers are revolutionizing dental clinics and hospitals, providing dental restoration, surgical planning, and personalized prosthetics. Orthopedic prosthetics and surgical instruments also benefit from 3D printing, improving surgical outcomes, operation time, and reducing post-surgical complications. Mechanical protection for tissues and organs is a promising area for 3D printing, with potential applications in organ transplantation and living cells using biomaterials. However, biosafety concerns and ethical issues surrounding the use of human cells and tissues need to be addressed by regulatory bodies like the Human Tissue Authority. Photopolymerization and Medical device manufacturers are using rapid prototyping to innovate, while healthcare professionals embrace the technology for prosthetics, surgical instruments, personalized prosthetics, orthotics, surgeon comfort, and fatigue prevention.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This 3d printing medical devices market report extensively covers market segmentation by  

Application 1.1 Orthopedic and spinal1.2 Dental1.3 Hearing aids1.4 OthersEnd-user 2.1 Hospitals and clinics2.2 Academic institutes2.3 Pharma and biotech companies2.4 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Orthopedic and spinal-  The 3D printing medical devices market encompasses the production of orthopedic and spinal implants using 3D printing technology. This technology enables the fabrication of standard-sized implants, patient-matched implants, and custom implants for individuals with deformities. Hospitals and ambulatory surgery centers are major end-users, as 3D printing allows for the creation of complex structures and individualized implants. Orthopedic and spinal applications dominate the market due to the rising prevalence of related disorders, increasing demand for personalized implants, and the need for advanced surfaces and structures. The technology’s ability to manufacture lattice structures and porous surfaces promotes bone ingrowth and improves implant stability. Titanium implants, commonly used in orthopedics, benefit from 3D printing’s ability to create greater porosity, enhancing bony ingrowth and improving implant stability. In the field of prosthetics, 3D printing significantly reduces manufacturing time and costs while maintaining functionality. The technology’s affordability makes it particularly suitable for children who quickly outgrow their prosthetic limbs. Vendors are increasing investments in R&D to develop advanced orthopedic and spinal implants, further fueling market growth. Key factors driving the market include the aging population, increasing prevalence of orthopedic and spinal disorders, and the demand for customized implants. These factors are expected to propel the growth of the global 3D printing medical devices market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products, including implants, hearing aids, bone scaffolds, surgical equipment, and more. The process begins with the creation of patient CAD images, which are then used to manufacture standard implants or personalized prosthetics, surgical instruments, and orthotics. The benefits of 3D printing in medical devices extend beyond patient comfort, as it also allows for the production of implantable and non-implantable medical devices using biomaterials, as well as drug testing and potential applications in organ transplantation and tissue engineering. Rapid prototyping and computer-aided manufacturing are key technologies driving the growth of this market, with healthcare professionals and medical device manufacturers embracing the technology to improve patient outcomes and surgical procedures.

Market Research Overview

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products such as implants, hearing aids, bone scaffolds, surgical equipment, and more. The use of patient CAD images ensures a perfect fit and optimal surgical outcomes, reducing operation time and post-surgical complications. 3D printing technology is being applied in various medical fields, including neurosurgery, orthopedics, and dentistry. For instance, it is used to create cranial implants, patient-specific models, and surgical tools for complex procedures. The use of biocompatible materials, such as titanium alloys and photopolymers, ensures the safety and effectiveness of 3D-printed medical devices. The market for 3D-printed medical devices is vast and diverse, encompassing elective surgical procedures, complex prosthetic limbs, brain designs, surgical instruments, and more. The technology is also being used in tissue engineering and organ transplantation, with the potential to print living cells and biomaterials. However, the use of 3D printing in medicine raises biosafety concerns and ethical issues, particularly with regard to the Human Tissue Authority and patient privacy. Medical device manufacturers are working to address these challenges through the use of CAD/CAM technology, rapid prototyping, and collaboration with healthcare professionals. The market for 3D-printed medical devices includes hearing aid manufacturers, dental clinics, hospitals, and surgical planning centers. The technology is also being used to create implantable and non-implantable medical devices, wearable medical devices, and diagnostic tools. The potential applications of 3D printing in medicine are vast, from surgical planning and dental restoration to remote patient monitoring and telemedicine. The future of medicine is undoubtedly 3D printed.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationOrthopedic And SpinalDentalHearing AidsOthersEnd-userHospitals And ClinicsAcademic InstitutesPharma And Biotech CompaniesOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/3d-printing-medical-devices-market-size-is-set-to-grow-by-usd-7-07-billion-from-2024-2028–increased-demand-for-personalized-or-customized-medical-devices-boost-the-market-technavio-302209578.html

SOURCE Infiniti Research, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Nearly 50% of Young People Resolve to Quit Nicotine in 2025

Published

on

By

EX Program by Truth Initiative Offers a Proven Path to Success

WASHINGTON, Dec. 23, 2024 /PRNewswire/ — Almost half (48%) of young people aged 18-24 are making quitting nicotine a priority for their 2025 New Year’s resolutions, according to new data from Truth Initiative® – the nation’s largest nonprofit public health organization dedicated to preventing youth and young adult nicotine addiction and empowering quitting for all.

 

This survey data* highlights a growing desire to break free from nicotine addiction and the urgent need for effective resources for 18- to 24-year-olds, among whom e-cigarette use is prevalent and dual use of cigarettes is a growing concern. For many, the journey to quit can feel daunting, especially for the scores of young people who think quitting means going “cold turkey” without a network of support. To meet this need, Truth Initiative is offering resources to help their resolutions stick and has launched Outsmart Nicotine, a new campaign designed to introduce young people to EX® Program, a comprehensive quitting resource developed in partnership with Mayo Clinic in 2008.

Empowering Young People with Tools and Encouragement Through EX Program

EX Program is a free cessation resource tailored to meet the unique challenges faced by young people. It offers proven, evidence-based tools designed to support quitting through personalized quit plans, interactive text messages, and 24/7 access to the nation’s most established online quit community. A randomized clinical trial among young adults published in JAMA Internal Medicine found that EX Program text message support can increase the odds of quitting by up to 40%, making EX Program one of the most effective resources for tackling nicotine addiction. These tools have helped millions quit nicotine over nearly two decades, solidifying EX Program as one of the most effective cessation resources available.

Redefining Quitter’s Day: Introducing “You Got This Day” as Part of the Outsmart Nicotine Campaign

Through the Outsmart Nicotine campaign, Truth Initiative is driving awareness of these tools with a series of ads that celebrate the small, everyday victories that lead to quitting nicotine for good. The campaign’s launch ad, “You Got This,” creates an uplifting tone with the iconic track “Can I Kick It?” by A Tribe Called Quest to inspire young people to take that first step toward a nicotine-free life.

“Quitting nicotine is hard, but it doesn’t have to be a lonely or impossible journey,” said Kathy Crosby, CEO and President of Truth Initiative. “With Outsmart Nicotine and the proven-effective EX Program, we’re showing young people that freedom from addiction is possible and within reach– and giving them the tools to quit smarter, not harder.”

Traditionally known as Quitter’s Day, the second Friday in January – January 10th in 2025 – marks the time of year when many people abandon their new year’s resolutions. Giving it a fresh perspective, Truth Initiative is renaming it “You Got This Day” to motivate young people to push through challenges and keep working toward their quit goals. The campaign reframes this day as a moment of empowerment, reminding young adults that quitting is difficult, but with the right support, it’s possible.

Take the First Step Toward Quitting

Truth Initiative invites young people to take the first step toward quitting by texting EXPROGRAM to 88709 or visiting exprogram.com. Organizations interested in EX Program’s enterprise solution can learn more at exprogram.com/enterprise.

*According to Truth Initiative Continuous Tracking Online (CTO) survey data collected October 17, 2024December 17, 2024, from 662 respondents.

About Truth Initiative
Truth Initiative® is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation EX® Program and national public education and prevention campaigns, we are leading the fight against youth and young adult tobacco use, which threatens to put a new generation at risk of lifetime nicotine addiction. Our rigorous scientific research and policy studies, community and youth engagement programs supporting populations at high risk of using tobacco, and innovation in tobacco dependence treatment continue to contribute to ending one of the most critical public health battles of our time. Based in Washington, D.C., our organization was established and funded through the 1998 Master Settlement Agreement between attorneys general from 46 states, five U.S. territories, and the tobacco industry. To learn more, visit truthinitiative.org.

About EX Program
EX® Program is a proven-effective tobacco cessation program, developed by Truth Initiative® with Mayo Clinic, that brings together the best evidence-based quitting approaches, interactive digital quitting programs, and the most established online quit community. EX Program has helped millions of youth and adults develop the skills and confidence to successfully quit. Truth Initiative research has shown that EX Program text messages can increase a user’s odds of quitting by up to 40%. To learn more, visit exprogram.com.

About EX Program Enterprise
Developed by Truth Initiative® with Mayo Clinic, EX® Program Enterprise is the best strategic partner for employers, health plans, and public health organizations to end smoking, vaping, and nicotine use. Sponsored users receive multimodal quitting support, available in both English and Spanish. Clients get real-time dashboards to track performance, year-round promotions, and expert client success guidance. To learn more about available options visit exprogram.com/enterprise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nearly-50-of-young-people-resolve-to-quit-nicotine-in-2025-302337746.html

SOURCE Truth Initiative

Continue Reading

Technology

Foxconn Announces Strategic Partnership With Zettabyte to Transform AI Data Centers

Published

on

By

TAIPEI, Dec. 23, 2024 /PRNewswire/ — Zettabyte, a global leader in AI data center software and infrastructure solutions, is proud to announce a strategic partnership with Hon Hai Technology Group (Foxconn), the world’s largest electronics manufacturer. This collaboration, underpinned by capital funding, aims to drive innovation and expand the adoption of energy-efficient AI solutions worldwide.

At the forefront of Zettabyte’s offerings is Zware, its advanced AI data center management software. Zware optimizes GPU performance, dramatically lowering energy usage while maximizing computing output. This cutting-edge solution empowers businesses to achieve unparalleled efficiency and sustainability in AI computing.

“We are thrilled to partner with Foxconn, a company renowned for its excellence in manufacturing and innovation,” said Kenneth Tai, Chairman of Zettabyte. “This partnership will accelerate the deployment of our technology, meeting the surging demand for high-performance, energy-efficient AI computing globally.”

Partnering with Zettabyte aligns with Foxconn’s commitment to advancing sustainable technologies. According to Foxconn, Zware’s ability to enhance AI data center operations while significantly reducing energy consumption opens opportunities to set new benchmarks for the future of AI data centers.

This collaboration underscores Zettabyte’s leadership in revolutionizing AI infrastructure and its dedication to providing transformative technologies to enterprises worldwide.

About Zettabyte

ZETTABYTE is a global innovator in AI data center technology, delivering solutions that redefine efficiency and sustainability in AI data centers. Its flagship software, Zware, is setting a new standard for sustainable and efficient AI computing.

About Foxconn

Established in 1974 in Taiwan, Hon Hai Technology Group (“Foxconn”) (TWSE: 2317) is the world’s largest electronics manufacturer and leading technological solutions provider, ranking 32nd among the Fortune Global 500. In 2023, revenue totaled TWD6.162 trillion (approx. US$198 billion or EUR183 billion)

View original content:https://www.prnewswire.com/apac/news-releases/foxconn-announces-strategic-partnership-with-zettabyte-to-transform-ai-data-centers-302338255.html

SOURCE Zettabyte

Continue Reading

Technology

Karma Automotive Collaborates with the Connected Vehicle Systems Alliance (COVESA), UC Riverside and ROADMEDIC.AI to Develop and Pilot Software and Standards for Next-Generation 9-1-1 Emergency Response Vehicle Communications

Published

on

By

At CES2025, a new vision is shared for standardizing the method that enables Software Defined Vehicles to more rapidly and robustly dispatch 9-1-1 Emergency Response Services to vehicle collisions 

IRVINE, Calif., Dec. 23, 2024 /PRNewswire/ — Karma Automotive, America’s only full-line ultra-luxury vehicle manufacturer, is passionate about enabling the proliferation of open standards in Software Defined Vehicle Architecture (SDVA) to increase industry collaboration, and to speed development as the expanded role of software redefines the driving experience aboard modern vehicles. With vehicle occupant safety as a preeminent focus in all vehicle development, Karma Automotive is collaborating with the Connected Vehicle Systems Alliance (COVESA), the University of California Riverside and ROADMEDIC.AI to develop standards-based software applications which leverage vehicle connectivity to provide robust and real-time insights to 9-1-1 first responders and the related eco-system.   

Developing technology that gets emergency responders to the scene faster to save lives

According to a paper published by the National Institute of Health (NIH), for every 1-minute increase in EMS response time, fatality odds increase by 2.6%. The goal of the effort is to drastically reduce emergency response times, and materially increase preparedness of responders when arriving at the site of a critical incident. Then, to validate software applications and communication protocols that have been validated in real-world applications that can be shared and easily deployed by the broader automotive industry.

To announce this project, Karma Automotive will join the COVESA Networking Reception and Demonstration at CES2025 on January 7 at 5pm at the Bellagio Hotel in Las Vegas, NV and showcase the ultra-exclusive, high-performance 2025 Karma Invictus. Karma Invictus is underpinned by the Karma Cloud Services platform that serves as the backbone for the development of the proposed safety system.

Enabling the detailed transmission of vital vehicle and occupant data in real-time could help responders increase preparedness to triage an incident, as contemporary automobiles carry tremendous amounts of data. Leveraging connectivity systems, a vehicle can directly identify number and location of occupants, severity of impact, location of the incident, vehicle extrication instructions and even driver biometrics. Software can be used to organize, parse, and transmit this data in real-time to parties based on their specific role in the 9-1-1 response eco-system.  When combined with vehicle-embedded and cloud-based AI, this data can be sorted and delivered independently, yet simultaneously to the diverse network of service providers that engage in incident response activities. Collectively, this effort is referred to as the ‘9-1-1 Dispatcher Visibility Demonstration Project’.

“Much of what we deliver to our customers in software should not be looked at as differentiating, but rather essential,” says Marques McCammon, President, Karma Automotive. “Safety for example is important to all industry players, and if we could standardize our approach to innovation in the space, we can not only improve the well-being of drivers universally, but also reduce development cost, and time getting new tech technologies to market. This philosophy is central to the Karma Automotive brand promise and our positioning as America’s only ultra-luxury automotive brand.”  

“Together with our partners, we look to democratize development and share the learnings to the benefit of the broader industry and the community at large,” continues McCammon, “and with upcoming Karma vehicles, this technology will be seamlessly integrated within our Karma Connect Vehicle Data Management and connectivity services platform.”

“This collaboration is the realization of a 25-year journey,” said Lawrence E. Williams, CEO and Founder of ROADMEDIC.AI. “Many times, it seemed like a pipe dream, but today, thanks to Karma Automotive’s shared vision, we are turning that dream into reality. Together, we are poised to revolutionize 9-1-1 emergency response systems and save countless lives.”

Next Generation 9-1-1 Technology: A Game Changer
Karma Automotive is the first OEM automotive partner to COVESA’s ‘9-1-1 Dispatcher Visibility Demonstration Project’. Working in collaboration with the University of California Riverside, the automaker will utilize 3rd Generation Karma Revero sport sedans to pilot the technology application and its related use cases. The results of this effort will then be shared with the greater COVESA community, National Highway Traffic Safety Administration (NHSTA), and other community members and stakeholders.

Existing 9-1-1 emergency response systems rely heavily on caller-based information, often supplemented by telematics systems transmitting data to manufacturer call centers. These systems, while useful, introduce delays and inconsistencies that can hinder timely emergency responses. By contrast, the Next Generation 9-1-1 Technology spearheaded by Karma Automotive and its partners will enable vehicles to instantly transmit vital, multi-layered crash data directly to 9-1-1 Emergency Communication Centers, bypassing intermediaries and saving precious seconds in emergency scenarios.

About Karma Automotive

Karma Automotive is America’s only full-line ultra-luxury vehicle manufacturer, and a pioneer of EREV (Extended Range Electric) vehicles which it manufactures at its Karma Innovation and Customization Center (KICC) in Moreno Valley, CA. Its Executive, Product Development, and Design headquarters are located in nearby Irvine, CA. The Karma portfolio embodies California’s spirit of innovation and entrepreneurial boldness, reflected by the signature Comet Line which is the central hallmark of Karma’s new design language. Sales of the 3rd Generation Karma Revero sport sedan, the world’s first luxury EREV plug-in hybrid, are now underway in the USA and EU, offering luxury balanced with conscientiousness delivered without compromise. Sales of Revero’s ultra-exclusive, performance-tuned stablemate, Karma Invictus, will begin in Q1 2025, followed by the Gyesera four-seater in Q4 2025.  The Karma Kaveya super-coupe, with up to 1,000HP and butterfly-doors, will arrive in Q4 2026, incorporating SDVA (Software-Defined Vehicle Architecture) developed in collaboration with Intel Automotive. Further, Karma Automotive will provide Tier 1’s and Original Equipment Manufacturers (OEMs) with business-to-business SDVA solutions, as it does today with Karma Connect, its proprietary Vehicle Data Management and Over-the-Air services platform, which presently provides services to the world’s second largest OEM. Karma Automotive’s dealer network spans North America, Europe, South America and the Middle East. (www.karmaautomotive.com) 

About ROADMEDIC.AI

ROADMEDIC.AI is an authorized automotive OEM Tier 1 supplier dedicated to improving 9-1-1 emergency response through instantaneous IP-based data transmission from motor vehicles to 9-1-1 centers. Their innovative solutions save lives and reduce harm in crash events. For more information, visit www.roadmedic.com.

About COVESA

The Connected Vehicle Systems Alliance (COVESA) is an open, member-driven global technology alliance accelerating the full potential of connected vehicles. By developing common approaches and technologies, COVESA provides a collaborative platform that empowers automotive software stakeholders and world-class developers to address challenges and opportunities in connected mobility and navigate the digital transformation of the automotive industry. Learn more about COVESA or join our community at www.covesa.global.

Media Contact:                                                                                                                                                           

Joe Richardson, (917) 716-6617                                                                              
Joe@BeautifulNoisePR.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karma-automotive-collaborates-with-the-connected-vehicle-systems-alliance-covesa-uc-riverside-and-roadmedicai-to-develop-and-pilot-software-and-standards-for-next-generation-9-1-1-emergency-response-vehicle-communications-302338073.html

SOURCE Karma Automotive

Continue Reading

Trending